<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The purpose of the present study was to determine the optimal management of nonobstructive <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in the early postoperative period after mitral valve replacement.Twenty cases of early <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were revealed by systematic transesophageal echocardiography (TEE) performed 9 days after surgical implantation of 229 St </plain></SENT>
<SENT sid="1" pm="."><plain>Jude prostheses </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were prospectively randomized into two groups: the first group received oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> (fluindione), and the second group was treated with a combination of oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> and aspirin </plain></SENT>
<SENT sid="3" pm="."><plain>The impact of the different therapies on prosthetic <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> was assessed by systematic TEE at 5 months </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> were nonobstructive and disappeared without fibrinolytic agents or surgery </plain></SENT>
<SENT sid="5" pm="."><plain>Seven large (&gt;/= 5 mm) <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> disappeared: in two patients after reintroduction of intravenous <z:chebi fb="5" ids="28304">heparin</z:chebi> and in five patients with an optimized oral treatment (<z:chebi fb="2" ids="50249">anticoagulants</z:chebi> alone in one patient, <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> associated with aspirin in four patients) </plain></SENT>
<SENT sid="6" pm="."><plain>In the 13 small (&lt; 5 mm) <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e>, 11 disappeared with an optimized oral treatment: <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> alone in nine patients and <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> associated with aspirin in two patients </plain></SENT>
<SENT sid="7" pm="."><plain>The other two small <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> treated with <z:chebi fb="5" ids="28304">heparin</z:chebi> alone initially persisted and finally disappeared with <z:chebi fb="5" ids="28304">heparin</z:chebi> associated with aspirin </plain></SENT>
<SENT sid="8" pm="."><plain>In the group with large <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e>, we recorded a 43% rate of <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo>, with more <z:hpo ids='HP_0011420'>deaths</z:hpo> and severe cerebral embolic events than in the patients with small <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Embolic events were associated with mobile <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>An optimized oral anticoagulation therapy with correction of the parameters of Virchow et al. is effective in the treatment of small prosthetic <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>For large <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e>, the high rate of <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> would appear to require a more aggressive approach such as an association of <z:chebi fb="5" ids="28304">heparin</z:chebi> with aspirin and TEE follow-up </plain></SENT>
</text></document>